| P2093 | author name string | Chien-Fu Hung | |
| | T-C Wu | |
| | Benjamin Yang | |
| | Jayne Knoff | |
| P2860 | cites work | Combination of apigenin treatment with therapeutic HPV DNA vaccination generates enhanced therapeutic antitumor effects | Q21284428 |
| | Global cancer statistics | Q22241238 |
| | Histone deacetylases specifically down-regulate p53-dependent gene activation | Q22253949 |
| | The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53 | Q24317677 |
| | Imiquimod: modes of action | Q28184438 |
| | Therapeutic vaccination with MVA E2 can eliminate precancerous lesions (CIN 1, CIN 2, and CIN 3) associated with infection by oncogenic human papillomavirus | Q28261838 |
| | MVA E2 recombinant vaccine in the treatment of human papillomavirus infection in men presenting intraurethral flat condyloma: a phase I/II study | Q28285807 |
| | A Novel Histone Deacetylase Inhibitor Exhibits Antitumor Activity via Apoptosis Induction, F-Actin Disruption and Gene Acetylation in Lung Cancer | Q28475503 |
| | Stressing the ubiquitin-proteasome system without 20S proteolytic inhibition selectively kills cervical cancer cells | Q28476783 |
| | Papillomaviruses and cancer: from basic studies to clinical application | Q29614745 |
| | Epidemiologic classification of human papillomavirus types associated with cervical cancer | Q29616213 |
| | Global burden of cancers attributable to infections in 2008: a review and synthetic analysis | Q29620303 |
| | Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: systematic review and meta-analysis | Q33233738 |
| | The E7 oncoprotein associates with Mi2 and histone deacetylase activity to promote cell growth | Q33292242 |
| | Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials | Q33383729 |
| | Serological response to an HPV16 E7 based therapeutic vaccine in women with high-grade cervical dysplasia | Q33620823 |
| | Intratumor injection of small interfering RNA-targeting human papillomavirus 18 E6 and E7 successfully inhibits the growth of cervical cancer. | Q44846001 |
| | Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and ISCOMATRIX adjuvant in women with cervical intraepithelial neoplasia | Q45142471 |
| | Efficient secretion of a modified E7 protein from human papilloma virus type-16 by Lactococcus lactis | Q45373619 |
| | The expression of the soluble isoform of hFlt3 ligand by recombinant vaccinia virus enhances immunogenicity of the vector. | Q45385399 |
| | Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes | Q45705136 |
| | Safety and immunogenicity of TA-HPV, a recombinant vaccinia virus expressing modified human papillomavirus (HPV)-16 and HPV-18 E6 and E7 genes, in women with progressive cervical cancer. | Q45729906 |
| | Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. | Q45734910 |
| | A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. | Q45769906 |
| | Systemic delivery of E6/7 siRNA using novel lipidic particles and its application with cisplatin in cervical cancer mouse models | Q45862754 |
| | Regression of high-grade cervical intraepithelial neoplasia with TG4001 targeted immunotherapy | Q46240097 |
| | A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. | Q46564278 |
| | A trial of SGN-00101 (HspE7) to treat high-grade anal intraepithelial neoplasia in HIV-positive individuals | Q46732942 |
| | Sequential effects of the proteasome inhibitor bortezomib and chemotherapeutic agents in uterine cervical cancer cell lines | Q46935977 |
| | Immunological responses in women with human papillomavirus type 16 (HPV-16)-associated anogenital intraepithelial neoplasia induced by heterologous prime-boost HPV-16 oncogene vaccination | Q47637442 |
| | Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine. | Q51820508 |
| | TA-CIN, a vaccine incorporating a recombinant HPV fusion protein (HPV16 L2E6E7) for the potential treatment of HPV16-associated genital diseases | Q53456269 |
| | Carcinogenicity of human papillomaviruses | Q58296516 |
| | Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine | Q60321494 |
| | Induction of Tumor-Specific CD4+ and CD8+ T-Cell Immunity in Cervical Cancer Patients by a Human Papillomavirus Type 16 E6 and E7 Long Peptides Vaccine | Q61626178 |
| | Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity | Q61626183 |
| | Vaccination with an adenoviral vector expressing calreticulin-human papillomavirus 16 E7 fusion protein eradicates E7 expressing established tumors in mice | Q64377372 |
| | Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial | Q73112587 |
| | Activation of MHC class I, II, and CD40 gene expression by histone deacetylase inhibitors | Q73306842 |
| | Amolimogene bepiplasmid, a DNA-based therapeutic encoding the E6 and E7 epitopes from HPV, for cervical and anal dysplasia | Q82811325 |
| | Oral immunization with a Lactobacillus casei vaccine expressing human papillomavirus (HPV) type 16 E7 is an effective strategy to induce mucosal cytotoxic lymphocytes against HPV16 E7 | Q82971865 |
| | Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer | Q43596600 |
| | Phase I/II trial of immunogenicity of a human papillomavirus (HPV) type 16 E7 protein-based vaccine in women with oncogenic HPV-positive cervical intraepithelial neoplasia | Q43700608 |
| | Association of human papillomavirus types 16 and 18 E6 proteins with p53. | Q43701619 |
| | Degradation of p53 by natural variants of the E6 protein of human papillomavirus type 16. | Q43931120 |
| | Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia | Q44653310 |
| | DNA vaccines for cervical cancer | Q33680693 |
| | Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments | Q33713435 |
| | A phase I trial of a human papillomavirus DNA vaccine for HPV16+ cervical intraepithelial neoplasia 2/3. | Q33834057 |
| | HPV31 E7 facilitates replication by activating E2F2 transcription through its interaction with HDACs | Q33841838 |
| | Therapeutic HPV DNA vaccines | Q33936427 |
| | Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses | Q33977826 |
| | Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments | Q34021545 |
| | Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. | Q34078674 |
| | Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference | Q34146791 |
| | Clinical studies of human papilloma vaccines in pre-invasive and invasive cancer. | Q34189203 |
| | Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). | Q34332463 |
| | Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers | Q34365543 |
| | HspE7 treatment of pediatric recurrent respiratory papillomatosis: final results of an open-label trial | Q34461719 |
| | Inhibition of HPV 16 E6 oncogene expression by RNA interference in vitro and in vivo | Q34522857 |
| | The effect of MG132, a proteasome inhibitor on HeLa cells in relation to cell growth, reactive oxygen species and GSH. | Q34608738 |
| | Activity of HspE7, a novel immunotherapy, in patients with anogenital warts | Q34635099 |
| | Vascular disrupting agent DMXAA enhances the antitumor effects generated by therapeutic HPV DNA vaccines | Q34708423 |
| | Pretreatment with cisplatin enhances E7-specific CD8+ T-Cell-mediated antitumor immunity induced by DNA vaccination | Q34732544 |
| | Listeria-based vaccines can overcome tolerance by expanding low avidity CD8+ T cells capable of eradicating a solid tumor in a transgenic mouse model of cancer | Q34797653 |
| | Clinician's guide to human papillomavirus immunology: knowns and unknowns | Q34982885 |
| | Immunotherapy against HPV16/18 generates potent TH1 and cytotoxic cellular immune responses | Q35049821 |
| | Control of cervicovaginal HPV-16 E7-expressing tumors by the combination of therapeutic HPV vaccination and vascular disrupting agents | Q35102014 |
| | Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. | Q35113700 |
| | Phase II trial of cetuximab in the treatment of persistent or recurrent squamous or non-squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study | Q35154219 |
| | Vaccination with dendritic cells transfected with BAK and BAX siRNA enhances antigen-specific immune responses by prolonging dendritic cell life | Q35234876 |
| | Epigallocatechin-3-gallate enhances CD8+ T cell-mediated antitumor immunity induced by DNA vaccination. | Q35234948 |
| | ZYC101a for treatment of high-grade cervical intraepithelial neoplasia: a randomized controlled trial | Q35644707 |
| | Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications | Q35828762 |
| | Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectives | Q35836881 |
| | Lm-LLO-Based Immunotherapies and HPV-Associated Disease | Q35838127 |
| | Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III | Q36052694 |
| | A placebo-controlled randomized HPV16 synthetic long-peptide vaccination study in women with high-grade cervical squamous intraepithelial lesions | Q36189261 |
| | Molecular mechanisms of human papillomavirus-induced carcinogenesis. | Q36303426 |
| | Molecular biology of human papillomavirus infection and cervical cancer | Q36441612 |
| | Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. | Q36483341 |
| | A pilot study of pNGVL4a-CRT/E7(detox) for the treatment of patients with HPV16+ cervical intraepithelial neoplasia 2/3 (CIN2/3). | Q36494733 |
| | Chapter 2: The burden of HPV-related cancers | Q36584354 |
| | Treatment with proteasome inhibitor bortezomib enhances antigen-specific CD8+ T-cell-mediated antitumor immunity induced by DNA vaccination | Q36874310 |
| | Cell-mediated immunological responses in cervical and vaginal cancer patients immunized with a lipidated epitope of human papillomavirus type 16 E7. | Q36898605 |
| | Cellular transformation by human papillomaviruses: lessons learned by comparing high- and low-risk viruses | Q36989890 |
| | Listeria-based HPV-16 E7 vaccines limit autochthonous tumor growth in a transgenic mouse model for HPV-16 transformed tumors | Q37010447 |
| | Low-dose radiation enhances therapeutic HPV DNA vaccination in tumor-bearing hosts | Q37109176 |
| | Molecular epidemiology of human papillomavirus | Q37133594 |
| | Histone deacetylase inhibitor AR-42 enhances E7-specific CD8⁺ T cell-mediated antitumor immunity induced by therapeutic HPV DNA vaccination | Q37198835 |
| | Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline | Q37223983 |
| | Combination of proteasome and HDAC inhibitors for uterine cervical cancer treatment | Q37271700 |
| | Molecular mechanisms of cervical carcinogenesis by high-risk human papillomaviruses: novel functions of E6 and E7 oncoproteins | Q37373523 |
| | The initial steps leading to papillomavirus infection occur on the basement membrane prior to cell surface binding | Q37453403 |
| | Human papillomavirus in head and neck cancer: its role in pathogenesis and clinical implications | Q37622609 |
| | Development of Proteasome Inhibitors as Therapeutic Drugs | Q38075795 |
| | A review of the current status of siRNA nanomedicines in the treatment of cancer | Q38111147 |
| | HDAC inhibitors trigger apoptosis in HPV-positive cells by inducing the E2F-p73 pathway. | Q38342582 |
| | Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia | Q39296306 |
| | Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma | Q39336768 |
| | Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins | Q39389688 |
| | Antitumor effects of (S)-HDAC42, a phenylbutyrate-derived histone deacetylase inhibitor, in multiple myeloma cells. | Q39632688 |
| | An HDAC inhibitor enhances the antitumor activity of a CMV promoter-driven DNA vaccine. | Q39784264 |
| | Development of an adenoviral vaccine against E6 and E7 oncoproteins to prevent growth of human papillomavirus-positive cancer | Q39905893 |
| | Therapeutic cancer vaccines in cervical cancer: phase I study of Lovaxin-C. | Q39906933 |
| | Immunization with a poly (lactide co-glycolide) encapsulated plasmid DNA expressing antigenic regions of HPV 16 and 18 results in an increase in the precursor frequency of T cells that respond to epitopes from HPV 16, 18, 6 and 11. | Q39982103 |
| | Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma | Q40102250 |
| | Enhancing dendritic cell vaccine potency by combining a BAK/BAX siRNA-mediated antiapoptotic strategy to prolong dendritic cell life with an intracellular strategy to target antigen to lysosomal compartments. | Q40182110 |
| | Antitumor effects of a novel phenylbutyrate-based histone deacetylase inhibitor, (S)-HDAC-42, in prostate cancer | Q40236236 |
| | Trichostatin-A enhances adaptive immune responses to DNA vaccination. | Q40269462 |
| | Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial | Q40312191 |
| | The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix | Q40391633 |
| | Superior therapeutic efficacy of alphavirus-mediated immunization against human papilloma virus type 16 antigens in a murine tumour model: effects of the route of immunization. | Q40494014 |
| | Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin | Q40516189 |
| | Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. | Q40582374 |
| | Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors | Q40601450 |
| | A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. | Q40746658 |
| | Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma. | Q40889921 |
| | The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells | Q41916312 |
| | Inhibitors of histone deacetylase arrest cell cycle and induce apoptosis in cervical carcinoma cells circumventing human papillomavirus oncogene expression | Q42657689 |
| | Synergistic induction of apoptosis in HeLa cells by the proteasome inhibitor bortezomib and histone deacetylase inhibitor SAHA. | Q42743806 |
| | A randomized, placebo-controlled, dose-escalation study to determine the safety, tolerability, and immunogenicity of an HPV-16 therapeutic vaccine in HIV-positive participants with oncogenic HPV infection of the anus. | Q43297040 |
| P433 | issue | 1 | |
| P921 | main subject | pathogenesis | Q372016 |
| P304 | page(s) | 18-32 | |
| P577 | publication date | 2014-03-01 | |
| P1433 | published in | Current obstetrics and gynecology reports | Q27724081 |
| P1476 | title | Cervical Cancer: Development of Targeted Therapies Beyond Molecular Pathogenesis | |
| P478 | volume | 3 | |